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Abstract
Background: Tumor-associated macrophages (TAMs) are the most abundant immune cells within the tumor
stroma and play a crucial role in tumor development. Although clinical investigations indicate that high levels of
macrophage (MF) infiltration into tumors are associated with a poor prognosis, the exact role played by TAMs
during tumor development remains unclear. The present study aimed to investigate dynamic changes in TAM
major histocompatibility complex (MHC) class II expression levels and to assess the effects of these changes on
tumor progression.
Results: Significant inhibition of tumor growth in the murine hepatocellular carcinoma Hepa1-6 model was closely
associated with partial TAM depletion. Strikingly, two distinct TAM subsets were found to coexist within the tumor
microenvironment during Hepa1-6 tumor development. An MHC class II
hi TAM population appeared during the
early phase of tumor development and was associated with tumor suppression; however, an MHC class II
low TAM
population became increasingly predominant as the tumor progressed.
Conclusions: Tumor progression was positively correlated with increasing infiltration of the tumor tissues by MHC
class II
low TAMs. Thus, targeting the transition of MF may be a novel strategy for drug development and
immunotherapy.
Background
Macrophages (MF)r e p r e s e n tt h em o s ta b u n d a n t
immune cell population in the tumor microenvironment
and play a key role in tumor development [1,2]. High
levels of MF infiltration into tumor tissues are asso-
ciated with a poor prognosis; this is particularly true for
hepatocellular carcinoma (HCC) [3-6]. Although a
decreased number of macrophages correlates with a
r e d u c t i o ni nt u m o rg r o w t hi ns e v e r a lt u m o rg r a f tm o d -
els [7,8], there are some exceptions. For example, deple-
tion of Kupffer cells worsens the prognosis of tumor-
bearing mice in peritoneal xenograft models because the
cancer cells are able to metastasize to the liver; thus, the
mice die from the increased tumor burden in the
absence of MF [9,10]. These contradictory reports high-
light the fact that little is known about the exact role of
tumor-associated macrophages (TAMs) during tumor
development.
MF are a highly heterogeneous cell population. This is
because their phenotypes and diverse functions are shaped
by the tumor microenvironment [11]. MF can be classi-
fied on the basis of two distinct activation states. Classi-
cally activated MF (M1), induced by IFN-g or microbial
products, produce high levels of proinflammatory cyto-
kines (IL-12 and IL-23), express major histocompatibility
complex (MHC) molecules and iNOS, and act as the pri-
mary source of anti-tumor immune cells [12-14]. In con-
trast, alternatively activated MF (M2), polarized by IL-4
or/and IL-13, secrete anti-inflammatory cytokines and are
characterized by increased arginase-1 activity and the
expression of Ym-1, MGL, Fizz1, and MSF [15-17]. Func-
tionally, M2 MF are thought to suppress inflammation
and to facilitate wound healing by promoting angiogenesis
and tissue remodeling [15,18]. A recent study shows that
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tionally distinct TAM subsets, and that these subsets pro-
mote tumor growth via different mechanisms [19]. HLA-
DR
high and HLA-DR
low IL-10
+ monocytes/MF have also
been identified in different regions within tumor tissues,
where they mediate T cell anergy through PD-L1 and
increase tumor cell migration and invasion [3-5,20]. How-
ever, the precise role played by these heterogeneous TAM
subsets in tumor progression has rarely been reported.
Clodronate (Cl2MDP)-encapsulated liposomes cause
irreversible damage to MF in vivo, thereby efficiently
decreasing the number of infiltrating MF [21,22]. Stra-
tegies incorporating liposome-mediated MF depletion
have been successfully used in murine tumor models of
teratocarcinoma, rhabdomyosarcoma, lung cancer, and
melanoma [7,23,24].
In the present study, Cl2MDP-liposomes were used to
partially deplete TAMs in a murine transplanted hepa-
toma model to investigate the exact role played by
TAMs during tumor development and the mechanisms
underlying TAM-mediated tumor progression.
Results
Partial depletion of MF using Cl2MDP-liposomes
To examine the extent of in vivo monocyte/MF deple-
tion by Cl2MDP, naïve mice were intravenously (i.v.)
injected with Cl2MDP-encapsulating liposomes 2 days
before tumor inoculation. As shown in Figure 1A, the
proportion of monocytes/MF in the peripheral blood
was approximately 5-7% before Cl2MDP-liposome
administration. This proportion decreased markedly (to
around 1%, p < 0.001) 24 h after the injection of
Cl2MDP-liposomes, before recovering (to about 3%, p <
0.05) 48 h later. The PBS liposome control did not affect
the number of monocytes/MF in vivo.W en e x te x a m -
ined the in vivo effects of Cl2MDP-liposomes on TAM
survival on Day 20 post-tumor inoculation. Immunohis-
tochemical staining with a rat anti-MF monoclonal anti-
body [RM0029-11H3], anti-F4/80, and anti-CD68
showed that the number of MF in tumor tissues was sig-
nificantly lower than that in control tissues (p < 0.001,
Figure 1B and 1C). This suggests that Cl2MDP-liposomes
efficiently deplete the number of TAMs in tumor-bearing
mice. In addition, we also assessed the survival of tumor
cells treated with Cl2MDP-liposomes in vitro. The results
showed that survival was not significantly affected (data
not shown). Thus, it appears that Cl2MDP-liposome
treatment may partially deplete MF without directly
affecting the growth of tumor cells in vivo.
Partial depletion of MF inhibits tumor progression in
tumor-bearing mice
To determine the effect of TAMs on tumor growth in
Hepa1-6 tumor-bearing mice, MF were depleted using
Cl2MDP-liposomes (Figure 2A). As shown in Figure 2B,
the rate of subcutaneous (s.c.) tumor growth in the
Cl2MDP-liposome-treated group was significantly slower
than that in the controls (p < 0.001). A similar experi-
ment was also conducted in a murine orthotopic tumor
model, in which tumors were induced by implanting
small tumor masses into the mouse livers (Figure 2C).
The results showed that macrophage depletion mediated
by Cl2MDP-liposome treatment partially inhibited
tumor growth (p < 0.001, Figure 2D). Taken together,
these results suggest that Cl2MDP-liposome-mediated
inhibition of tumor growth is positively correlated with
a decrease in TAM infiltration.
Tumor progression correlates with the level of TAM
infiltration
To further examine the role of TAMs in tumor progres-
sion in murine models, several TAM-associated suppres-
sive factors were analyzed in situ.F i g u r e3 As h o w st h a t
expression of IL-10, TGF-b,M M P - 9a n dV E G Fi nt h e
tumor microenvironment was markedly reduced in the
Cl2MDP liposome-treated group compared with that in
the control vehicle-treated group. This result suggests
that increased TAM infiltration contributes to the for-
mation of a suppressive tumor microenvironment and
the promotion of tumor growth. This conclusion was
verified by examining CD31 expression (Figure 3B,C).
Taken together, these data show that tumor infiltration
by TAMs plays an important role in tumor progression.
TAMs in tumor-bearing mice are a heterogeneous
population
To further elucidate the mechanisms underlying TAM-
mediated tumor growth, TAMs were isolated and phe-
notypically characterized. Single cells were recovered
from tumor tissues at the indicated time points. Two
heterogeneous TAM populations were identified based
on their expression of MHC class II molecules, namely
MHC class II
low and MHC class II
hi (Figure 4A). Strik-
ingly, the MHC class II
low TAM subset expressed high
levels of y m 1 ,m g l 1 / 2 ,f i z z 1 ,a r g - 1 ,m s f ,i l - 1 0 ,t g f - b,
mmp-9, vegf,a n dptge2, whereas the MHC class II
hi
TAM subset expressed high levels of il-1b, il-6, il-12,
and inos (Figure 4B). Next, the differential expression of
IL-10 between both TAM populations was examined in
co-staining experiments. The proportion of IL-10-
expressing MF in the MHC class II
low TAM subset was
approximately 42% on Day 10 post-tumor inoculation,
whereas the proportion in the MHC class II
hi TAM sub-
set was only around 18% (Figure 4C). We next exam-
ined changes in the levels of the two subsets within
tumor tissues during tumor progression. The proportion
of MHC class II
hi TAMs was higher than that of MHC
class II
low TAMs during the early stages of tumor
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and number of MHC class II
low TAMs markedly
increased as the tumor progressed (Figure 4E), indicat-
ing that infiltrating MF preferentially differentiate into
MHC class II
low TAMs as tumors continue to grow.
To determine the effects of Cl2MDP-liposomes on
the two TAM subsets, we examined expression of
MHC class II in both untreated and TAM-depleted
tumors using immunohistochemistry and flow cytome-
try. As shown in Figure 4F, there were differences in
the expression of MHC class II between untreated and
TAM-depleted tumors. Although the total number of
TAMs expressing MHC class II decreased after treat-
ment with Cl2MDP-liposomes, the number of MHC
class II
low TAMs in the treated tumors was signifi-
cantly lower than in untreated tumors. In contrast, the
number of MHC class II
hi TAMs was not significantly
affected by treatment with Cl2MDP-liposomes (Figure
4G and 4H). Taken in the context of the data pre-
sented in Figure 3A, these results suggest that after
depleting the majority of TAMs, the remaining MF
undergo transition from MHC class II
hi to MHC class
Figure 1 Effect of Cl2MDP-liposome treatment on the survival of MF in mice. (A) Cl2MDP-liposome-mediated depletion of monocytes/MF
from the peripheral blood of mice. Each value represents the mean proportion of monocytes/MF ±S D( n = 6). (B) The survival of TAMs in
tumor-bearing mice was examined by immunostaining with the rat monoclonal anti-MF antibody [RM0029-11H3] and antibodies to F4/80 and
CD68 after treatment with Cl2MDP-liposomes. (C) Infiltrating TAMs were counted at × 400 magnification (a 0.17 mm
2 field). Data represent the
mean MF number per field ± SD (10 fields per tumor, 5 tumors per group). *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Student’s t-test).
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low at an accelerated rate, resulting in delayed tumor
growth.
Taken together, these data demonstrate that two TAM
subsets exist within the tumor tissues and that transition
between the two sub-populations is closely related to
tumor progression, during which the predominant MHC
class II
hi subset may shift to an MHC class II
low subset.
MHC class II
low TAMs promote tumor growth and MHC
class II
hi TAMs promote tumor inhibition
To further characterize the effects of the two heteroge-
neous TAM subsets on tumor progression, the MHC
class II
hi and MHC class II
low cells were sorted and
adoptively transferred to tumor-bearing mice 2 days
after tumor inoculation. As expected, compared with
the control group (PBS), tumor progression was signifi-
cantly induced in mice treated with MHC class II
low
TAMs, but markedly inhibited in mice treated with
MHC class II
hi TAMs (Figure 5A). These results were
verified by measuring tumor weight and size (Figure
5B). We then analyzed the expression of MHC class II
molecules within the tumor tissues using immunohisto-
chemistry. As shown in Figure 5C, the number of MHC
class II-expressing cells in the tumors from the control
mice and from mice treated with MHC class II
low was
significantly lower than that in the tumors from mice
treated with MHC class II
hi TAMs. These results sug-
gest that tumor progression is positively correlated with
the number of infiltrating MHC class II
low TAMs, but
negatively correlated with the number of infiltrating
MHC class II
hi TAMs.
MHC class II
low TAMs inhibit T cell activation and promote
invasion of tumor cells by secreting immunosuppressive
factors
Since T cell-mediated cellular immunity plays a critical
role in the regulation of tumor progression, we exam-
ined the contribution made by each of the TAM subsets
to the activation of T cells. A T cell polyclonal activa-
tion assay was performed using the TAM subsets.
Sorted MHC class II
hi and MHC class II
low TAMs were
co-cultured with allogeneic splenocytes in the presence
of an anti-CD3 antibody. T cell proliferation was mea-
sured using the BrdU assay. MHC class II
hi TAMs pro-
moted anti-CD3-induced T cell proliferation in a dose-
dependent manner, whereas MHC class II
low TAMs
suppressed anti-CD3-induced T cell proliferation. The
increasing number of MHC class II
low TAMs correlated
Figure 2 MF depletion by Cl2MDP-liposomes inhibits tumor growth in the Hepa1-6 induced tumor model. (A) Experimental outline for
MF depletion by administration of Cl2MDP-liposomes in s.c. tumor-bearing mice. Saline and PBS-liposomes were used as the controls. (B) Size of
the s.c.-transplanted tumors (n = 15). Data are representative of three independent experiments. (C) Experimental outline for administration of
Cl2MDP-liposomes in orthotopic tumor-bearing mice. (D) Weights of orthotopically transplanted tumors (n = 12). The bars represent the mean ±
SD; *p < 0.05, ***p < 0.001 (unpaired Student’s t-test).
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class II
low TAMs express high levels of IL-10 and TGF-
b, which may contribute to T cell inactivation. This was
examined using antibodies to block IL-10 and TGF-b.
As shown in Figure 6B, T cell activation was signifi-
cantly inhibited in the absence of the blocking antibo-
dies. This was reversed by neutralizing IL-10 and TGF-
b. These results were further verified by measuring the
levels of IL-10 and TGF-b in the supernatants of TAMs
co-cultured with splenocytes (Figure 6C). The results
suggest that MHC class II
low TAMs contribute to tumor
progression via IL-10/TGF-b-mediated suppression of T
cell activation.
We also examined the expression of MMP-9 and
VEGF in both subsets using RT-PCR and western blot-
ting. The expression of MMP-9 and VEGF in MHC
class II
hi TAMs was lower than that in MHC class II
low
TAMs (Figure 6D and 6E). To assess the effects of the
different TAM subsets on the invasiveness and metasta-
sis of mouse hepatoma cells, an invasion assay was per-
formed using HCC cells. The invasiveness of cancer
cells was markedly enhanced by MHC class II
low TAMs
(p < 0.01; Figure 6F and 6G). This result suggests that
MHC class II
low TAMs promote cell invasion to a
greater extent than MHC class II
hi TAMs.
Discussion
This study showed that partial depletion of MF by
Cl2MDP-liposomes efficiently modulates the tumor
microenvironment and tumor progression in the Hepa1-
6 cell-transplanted tumor model. Furthermore, heteroge-
neous TAM populations were found to coexist in the
tumor microenvironment. MHC class II
hi TAMs
appeared during the early phases of tumor development
and showed tumor suppressive activity. In contrast,
MHC class II
low TAMs became more dominant as the
tumors progressed, and were alternatively (rather than
classically) activated and promoted tumor growth.
Cl2MDP is a bisphosphonate developed to treat osteo-
lytic bone disease [25]. The free drug does not easily
enter cells and has an extremely short half-life in the
circulation and body fluids. However, it is ingested spe-
cifically by MF and has a longer half-life when encapsu-
lated in liposomes [21,22]. MF are irreversibly damaged
Figure 3 Immunohistochemical analyses of immunosuppressive molecules after Cl2MDP-liposome treatment. (A) Expression of IL-10,
TGF-b, VEGF, and MMP-9 was evaluated by immunostaining. Original magnification: × 400. Insets: representative cells expressing VEGF and MMP-
9. Arrowheads show positively-stained cells. (B) Examination of CD31 expression in tumors by immunostaining. (C) CD31-positive microvessel
density was evaluated by counting at × 400 magnification (a 0.17 mm
2 field). Data are expressed as mean vessel number per field ± SD (10
fields per tumor, 5 tumors per group). ***p < 0.001 (unpaired Student’s t-test).
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undergo apoptosis because of the formation of toxic
ATP analogues [21,22,25]. This strategy efficiently
reduces the number of MF in vivo and has been used
successfully to investigate the role of MF in animals
[7,23,24,26,27]. The results of the present study show
that treatment with Cl2MDP-liposomes efficiently and
specifically reduces the number of TAMs in a murine
transplanted hepatoma model. Although tumor regres-
sion following TAM depletion has been reported in a
human hepatoma xenograft nude mouse model treated
with sorafenib, treatment with Cl2MDP-liposomes alone
has no inhibitory effect on tumor growth in tumor-bear-
ing nude mice [27]. This disparity can be explained by
the absence of T cell-mediated cellular immune
responses in nude mice. Another possible explanation is
that the effects of Cl2MDP-liposome treatment are
limited in nude mice. That said, the role of MF in
tumor-bearing mice and rats is still extensively studied
using Cl2MDP-liposomes.
The choice of administration route used for liposome
treatment enables some degree of selectivity with
respect to the MF populations targeted [28]. Injection
of Cl2MDP-liposomes via the i.v. route depletes MF in
liver, spleen, bone, and circulation, whereas s.c. injection
only affects MF in the lymph nodes [28]. A recent
study shows that intratumoral (i.t.) injection of
Cl2MDP-liposomes into tumor-bearing mice signifi-
cantly delays tumor growth [29]. Although the total
number of MF affected by i.p. injection is higher than
that affected by other routes (e.g. the i.v. route), it
necessitates the use of a relatively large volume of
Cl2MDP-liposomes [28]. Thus, in the present study, we
injected Cl2MDP-liposomes via the i.v. route for
Figure 4 Infiltration of Hepa1-6 tumors by distinct TAM subsets. (A) Identification of distinct TAM subsets in single-cell suspensions
obtained from tumors on Day 21 after tumor inoculation (n = 5). (B) Phenotypic analysis of classically versus alternatively activated TAM subsets
using qRT-PCR. Data are representative of three independent experiments. The bars represent the mean ± SD. (C) Expression of IL-10 by sorted
TAMs in tumors on Day 10 after tumor inoculation (n = 5). (D) Dynamic analysis of two distinct subsets from tumors on Days 7, 14, 21, and 28
after tumor inoculation. Tumor weights are shown above the FACS plots (n = 5). (E) Number of TAMs (F4/80
+MHC II
low cell population versus
F4/80
+MHC II
hi cell population) per tumor at the indicated time points. (F) Expression of MHC class II by untreated and TAM- depleted tumors
analyzed by immunohistochemistry. Insets: representative cells expressing high and low levels of MHC class II (n = 5) (× 400 magnification). (G)
Analysis of MHC class II
hi and MHC class II
low TAMs in untreated and TAM-depleted tumors on Day 20 after treatment with Cl2MDP-liposomes (n
= 5). (H) Proportion of MHC class II
hi and MHC class II
low TAMs in the untreated and TAM-depleted tumors (n = 5). The bars represent the mean
± SD; **p< 0.01, ***p < 0.001 (unpaired Student’s t-test).
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6 sorted F4/80
+MHC II
hi and F4/80
+MHC II
low cells
derived from tumors on Day 21 after inoculation (n = 20) were injected into the tumor tissues of other mice 2 days after tumor inoculation (n
= 4). PBS was used as the control. (A) Tumor size. (B) Tumor weight. (C) MHC class II expression in the differently treated tumors was examined
by immunostaining and counting (n = 4) (× 400 magnification). The bars represent the mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired
Student’s t-test).
Figure 6 MHC class II
low/hi TAM subsets modulate T cell proliferation through IL-10/TGF-b production and invasion and migration of
tumor cells through MMP-9 and VEGF production. (A) Suppression or promotion of anti-CD3-induced T cell proliferation by different TAM
subsets (n = 3). (B) The suppression of T cell polyclonal activation was reversed by neutralizing IL-10 and TGF-b (n = 3). (C) IL-10 and TGF-b
levels after co-culture of TAMs and splenocytes (n = 3). (D) RT-PCR analysis of mmp-9 and vegf expression. (E) Western blot analysis of MMP-9
and VEGF expression. (F) Representative images showing tumor cell migration taken 24 h after co-culture of Hepa1-6 cells and TAMs (× 400
magnification). Images shown are representative of three independent experiments. (G) Number of migrated tumor cells. The bars represent the
mean ± SD; **p < 0.01 (unpaired Student’s t-test).
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t. routes in the s.c.-implanted tumor model, to maxi-
m a l l yr e d u c et h en u m b e ro fTAMs infiltrating the
tumors and to minimize any possible toxic side effects
mediated by the Cl2MDP-liposomes. We did not exam-
ine the effect of i.v. or i.t. injection of Cl2MDP-lipo-
somes on s.c.-transplanted tumors, as the combination
of i.v. injection plus i.t. administration was thought to
be the effective procedure for depleting TAMs in our
models. However, the choice of injection route needs to
be validated by additional investigations.
Unlike lymphocytes, MF do not express specific mar-
kers, although F4/80, CD68, and CD11b are commonly
used to label these cells. A rat monoclonal anti-MF
antibody [RM0029-11H3] was developed against isolated
mouse MF and was used to label MF in some studies
[30,31]. A recent study shows that MF can be classified
into CD11b
+Ly6C
hi and CD11b
+Ly6C
low populations
based on their expression of CD11b and Ly6C [19]. Dif-
ferences in the expression levels of these biomarkers can
be used to examine MF subpopulations. In the present
study, histological analyses showed that TAMs could be
exclusively labeled using antibodies to F4/80, CD68, and
with the rat monoclonal anti-MF antibody [RM0029-
11H3], although there were quantitative differences in
the expression levels of these biomarkers.
MF within tumors are polarized toward the M2 pheno-
type by tumor-derived factors, which cause them to pro-
mote tumor progression [3,4,14,32-34]. IL-10 and TGF-b
play an important role in promoting tumor growth. IL-10
is likely to induce TAM-derived CCL18, which is a che-
moattractant for naive T cells, followed by T cell anergy
via altered STAT1 expression [35-37]. The results of the
present study showed that MHC class II
low TAMs
expressed high levels of IL-10 and TGF-b.T h er o l eo f
these cytokines was verified, at least in part, by blocking
cytokine-mediated T cell suppression in vitro using anti-
IL-10 and anti-TGF-b mAbs. Interestingly, the levels of IL-
10 and TGF-b, which are expressed by MHC class II
low
TAMs in the TS/A tumor model, are low [19]. This may
be explained by disparities in the experimental models; for
example, the constitution of the tumor microenvironment
m a yb ed i f f e r e n t .T h e r em a ya l s ob eam o r ec o m p l e x
mechanism that mediates suppression of T-cell polyclonal
activation by MHC class II
low TAMs in the TS/A tumor
model. However, MHC class II
low TAMs in the Hepa1-6
tumor model are more likely to mediate suppression of T-
cell activation via production of IL-10 and TGF-b.
Although the exact mechanisms underlying MHC class
II
low TAM-mediated suppression of tumor growth in vivo
are yet to be elucidated, our observations provide an
insight into how TAMs subvert anti-tumor adaptive
responses and redirect T cell activity to favor tumor
growth. TAM-mediated T cell anergy may play an
important role in tumor promotion. Our investigation also
shows that MHC class II
low TAMs promote invasion of
Hepa1-6 cells via the production of angiogenesis-associated
molecules such as VEGF and MMP-9. This suggests that
MHC class II
low TAM subset-mediated angiogenesis could
be another important cause of runway tumor progression.
Thus, the mechanisms underlying TAM subset-mediated
tumor growth are intricate and need further study.
TAMs are a heterogeneous population that may have
both inhibitory and stimulatory influences on malignant
growth [38]. The transition between complex pheno-
types depends on the tumor milieu [19,39]. For example,
studies in patients with HCC reveal that two distinct
populations (HLA-DR
high and HLA-DR
low IL-10
+)o f
monocytes/MF exist within different regions of the
tumor, which modulate T cell activation via different
mechanisms [4,5]. Although the MHC class II
hi TAM
and MHC class II
low TAM populations in the TS/A
tumor model mediate tumor progression through differ-
ent mechanisms, dynamic analysis of TAM subsets
shows that there is a balance between these populations
[19]. This is consistent with our observation that a shift
from MHC class II
hi to MHC class II
low in the Hepa1-6
tumor model correlates with tumor progression. Infil-
trating monocytes are more likely to differentiate into
MHC class II
hi TAMs during the early phase of tumor
development, whereas MHC class II
low TAMs become
gradually more prominent as the tumors progress. How-
ever, this study also showed that MHC class II
low TAMs
promoted tumor progression, whereas MHC class II
hi
TAMs had a suppressive effect on tumor growth.
Further investigation into the effects of the tumor
microenvironment on the balance between TAM subsets
may help to explain this discrepancy.
Conclusions
This study shows that TAM depletion causes tumor
regression in a murine hepatoma xenograft mouse
model. Heterogeneous TAM subsets co-exist within the
tumor microenvironment, and there is a transition from
MHC class II
hi to MHC class II
low TAMs that correlates
with tumor progression. The MHC class II
hi TAM popu-
lation appears during the early phase of tumor develop-
ment and contributes to tumor suppression, whereas the
MHC class II
low population becomes dominant as the
tumor progresses. MHC class II
low TAMs are alterna-
tively activated and promote tumor growth. Therefore,
targeting the transition of MF m a yb ean o v e ls t r a t e g y
for drug development and immunotherapy.
Methods
Reagents
The following reagents were used in the study: Rat anti-
mouse F4/80 mAb (AbD; Serotec, Kidlington, UK), a rat
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body against isolated mouse MF;A b c a m ,C a m b r i d g e ,
MA, USA), rat anti-mouse MHC class II (I-A
b,d,q/I-E
d,k)
mAb (BioLegend, San Diego, CA, USA), and rat anti-
mouse-IL-10/TGF-b and rabbit-anti-mouse-CD31/
VEGF/MMP-9 mAb (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The IL-10 and TGF-b enzyme-linked
immunosorbent assay (ELISA) kits were purchased from
Bender Medsystems (GmbH, Vienna, Austria). All fluor-
escently-labeled mAbs and isotype control mAbs were
obtained from eBioscience (San Diego, CA, USA). Clo-
dronate (dichloromethylene diphosphonate, Cl2MDP)
was a generous gift from Roche Diagnostics (GmbH,
Mannheim, Germany). All other reagents were obtained
from Sigma. (St Louis, MO, USA) unless otherwise
indicated.
Animal care
Female C57BL/6 and BALB/c mice (6-8 weeks old) were
obtained from Beijing Vital River Experimental Animals,
Co. Ltd. All animal experiments were approved by the
Laboratory Animal Committee of Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of
Science.
To investigate the effects of Cl2MDP-liposomes on
tumor growth, naïve mice were first injected i.v. with
200 μlo fC 1 2MDP-liposome suspension 2 days prior to
tumor inoculation. Peripheral blood (50 μl) was col-
lected retro-orbitally 0, 24, and 48 h after treatment and
immediately transferred to ethylenediaminetetraacetic
acid (EDTA) -containing tubes (BD Bioscience). Whole
blood cells were stained with APC-conjugated anti-
CD11b and FITC-conjugated anti-F4/80 mAbs for 30
min in the dark on ice. The cells were then washed and
the red blood cells lysed with FACS lysis buffer (BD
Bioscience). The remaining white blood cells were
washed again and resuspended in PBS containing 1%
fetal calf serum (FCS). Flow cytometry data were
acquired using a BD FACSAria and analyzed using
FLOWJO software version 7.6.0 (Tree Star, Inc., Ash-
land, OR, USA). After tumor inoculation, mice were
treated with Cl2MDP-liposomes via both i.v. (200 μl)
and i.t. (50 μl) routes on Days 3, 8, 13, and 18. PBS-lipo-
somes and saline were used as the controls. Tumor size
was measured every 4 days using calipers and calculated
using the formula: 0.52 × a × b
2 (a: long diameter of the
tumor; b: short diameter of the tumor). After 20 days,
tumor-bearing mice were sacrificed for further analysis.
For the orthotopic tumor model, 200 μlo fC l 2MDP-
liposomes were injected i.v. on Day 2 before surgery,
and at 3, 8, and 13 days after surgery. After 15 days,
mice were sacrificed and the tumors were removed and
weighed.
Preparation of Cl2MDP-liposomes
Cl2MDP-liposomes were prepared as described pre-
viously [21,22]. Briefly, a mixture of 8 mg of cholesterol
and 86 mg of phosphatidylcholine was prepared in
chloroform in a round-bottom flask. The thin film on
the interior of the flask after low-vacuum evaporation at
37°C was dissolved in 10 ml of 0.7 M Cl2MDP solution
and incubated for 2 h at room temperature under
Argon gas protection, followed by 3 min of sonication
and another 2 h of incubation at room temperature.
The liposomes were washed five times by centrifugation
to remove any free drugs. The final pellet was resus-
pended in 4 ml of sterile PBS. The control liposomes
were prepared using PBS. Cl2MDP-liposomes and PBS-
liposomes were stored at 4°C for 2 weeks.
Cell culture and tumor models
The murine HCC cell line, Hepa1-6, and the murine
MF cell line, RAW264.7, were cultured in DMEM sup-
plemented with 10% FCS and 1% penicillin-streptomycin
at 37°C. For the s.c. tumor model, 100 μlo fs e r u m - f r e e
RPMI 1640 containing 2 × 10
6 Hepa1-6 cells was
injected s.c. into the right anterior axillary fossa of naïve
mice. A palpable spherical mass emerged after 4 to 6
days.
An orthotopic hepatoma model was created by trans-
plantation of a small tumor mass into the left liver lobe
of naïve mice. Briefly, 2 × 10
6 Hepa1-6 cells was injected
s.c. into the right anterior axillary fossa of naïve mice.
The mice were sacrificed when the hepatoma grew pro-
gressively and the tumor diameter exceeded 10 mm.
T h et u m o r sw e r er e m o v e da n dc h o p p e di n t os m a l l
pieces (about 1 mm
3) using a scalpel and forceps. The
small masses were surgically implanted under anesthesia
(a small tumor mass/mouse) into one site in the left
liver lobe of mice treated with Cl2MDP-liposomes, PBS-
liposomes, or saline.
Immunohistochemical analysis
Preparation of histological specimens (from tumors on
Day 20 after treatment with Cl2MDP-liposomes or from
tumors on Day 10 after adoptive transfer of sorted
TAM populations) and immunostaining were carried
out as described previously [35]. Antigen retrieval was
performed under high pressure in 10 mM EDTA buffer
(pH 8.0) before incubation with primary antibodies to
F4/80, CD68, or rat monoclonal anti-MF [RM0029-
11H3] or IL-10, TGF-b,V E G F ,M M P - 9 ,C D 3 1a n d
MHC class II. Brightfield images were then captured
and analyzed.
The number of infiltrating MF and the CD31-positive
microvessel density were counted in 10 random fields at
× 400 magnification (a 0.17 mm
2 field), and the results
Wang et al. BMC Immunology 2011, 12:43
http://www.biomedcentral.com/1471-2172/12/43
Page 9 of 12were expressed as the mean number per field ± SD (10
fields per tumor, 5 tumors per group).
Isolation of TAMs and splenocytes
Single cells within the tumor tissue were isolated as
described previously with some modifications [40].
Briefly, solid tumors were harvested from tumor-bear-
ing mice on Days 7, 14, 21, and 28 after tumor inocu-
lation or harvested under sterile conditions from
tumor-bearing mice untreated or treated with
Cl2MDP-liposomes. The tumors were chopped into
small pieces using scissors and forceps before incuba-
tion with a mixture of enzymes dissolved in RPMI
1640 (400 U/ml collagenase type IV, 0.05 mg/ml col-
lagenase type I, 0.025 mg/ml hyaluronidase, 0.01 mg/
ml DNase I and 0.2 units/ml soybean trypsin inhibitor)
for 30 min at 37°C. Cells were recovered by centrifuga-
tion and resuspended in PBS, containing 1% FBS. The
debris and red blood cells were removed using the
Ficoll density gradient method. F4/80
+MHC II
hi and
F4/80
+MHC II
low cells were analyzed and sorted by
flow cytometry. Briefly, cells were resuspended in PBS
supplemented with 1% FCS, and 1 × 10
7 cells were
incubated with 10 μg of FITC-conjugated F4/80 mAb
and 0.2 μg of PE-conjugated MHC class II mAb for 30
min on ice. The cells were then washed with PBS sup-
plemented with 1% FCS to remove unbound Abs. The
F4/80
+MHC II
hi and F4/80
+MHC II
low cell populations
were analyzed and sorted using a FACSAria flow cyt-
ometer. All data were analyzed using FLOWJO soft-
ware version 7.6.0. The purity of the cell populations
exceeded 90%.
Single cells were also prepared as described above on
Day 10 after tumor inoculation. Briefly, 1 × 10
7 sorted
cells were incubated with 2 μg of APC-conjugated F4/80
mAb and 0.2 μg of PE-conjugated MHC class II mAb
for 30 min on ice. The cells were then washed with PBS
supplemented with 1% FCS. After fixation, permeation,
and washing, the cells were stained with 10 μg of FITC-
conjugated IL-10 mAb. The unbound antibodies were
removed by washing. The expression of IL-10 by F4/80
+MHC II
hi and F4/80
+MHC II
low cells was then
analyzed.
Naïve BALB/c mice (6-8 weeks old) were sacrificed
and the spleens were harvested using syringes and for-
ceps and single cell suspensions obtained. Red blood
cells were removed with ACK lysis buffer (0.15 M
NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH 7.3), and the
remaining splenocytes were washed twice by centrifuga-
tion. The splenocytes were counted, diluted to the
appropriate concentration in RPMI 1640 supplemented
with 10% FCS and 1% penicillin-streptomycin for further
investigation.
Real-time quantitative reverse transcription PCR (qRT-
PCR) and reverse transcription PCR (RT-PCR)
Total RNA from the sorted TAM populations was iso-
lated using Trizol according to the manufacturer’s
instructions. qRT-PCR to examine the expression of
ym1, mgl1/2, fizz1, arg-1, msf, il-10, tgf-b,m m p - 9 ,v e g f ,
ptge2, il-1b, il-6, il-12,a n dinos was performed using a
One Step SYBR
® PrimeScript™ RT-PCR kit according
to the manufacturer’s instructions (Takara, Dalian,
China). b2-mG was used as a the reference gene.
Two-step RT-PCR was performed to examine the
expression of mmp-9 and vegf in the sorted TAM popu-
lations. cDNA was synthesized from 2 ug of total RNA
using Moloney murine leukemia virus reverse transcrip-
tase (Takara) after DNase treatment. The PCR condi-
tions were as follows: 94°C for 5 min followed by 30
cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 40 s,
with a final extension at 72°C for 7 min. The b2-mG
g e n ew a su s e da sar e f e r e n c e .T h eP C Rp r o d u c t sw e r e
analyzed by gel electrophoresis.
Western blot analysis
Total proteins were extracted from the sorted TAM
populations and electrophoresed on 10% SDS polyacry-
lamide gels. The proteins were then transferred to poly-
vinylidene fluoride membranes (Millipore, MA, USA).
Non-specific binding was blocked with 5% (wt/vol) non-
fat milk in PBS-Tween-20 (0.1% vol/vol). The mem-
branes were then incubated with primary antibodies
against MMP-9 and VEGF at 4°C overnight and with
the appropriate secondary antibodies at room tempera-
ture for 1 h. Immobilon Western HRP Chemilumines-
cent Substrate (Cell Signaling Technology, MA, USA)
was used to detect the specific signals, and the band
intensity was then visualized.
Invasion and migration assays
Tumor cell invasion assays were performed using a
Transwell apparatus (Corning, NY, USA) with an 8-
μm-pore polycarbonate filter membrane. The upper
sides of the membranes were pre-coated with Matrigel
matrix (BD, NJ, USA) according to the manufacturer’s
instructions. Sorted TAMs (2 × 10
5) were pre-seeded in
the lower chamber. The upper chamber was seeded
with 1 × 10
4 Hepa1-6 cells and inserted into the lower
chamber. After incubation for 24 h, the cells on the
interior of the upper chamber were removed by swab-
bing with cotton swabs. The polycarbonate membranes
were fixed in methanol for 20 min and stained with
0.1% crystal violet for 15 min. The number of cells
migrating to the underside of the membranes was
counted in five randomly selected fields under a micro-
s c o p e .F o rt h em i g r a t i o na s s a y ,t h es a m ep r o c e d u r ew a s
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gel to the top of the upper chamber membrane.
T cell suppression assays
For the T cell suppression assays, 1 × 10
5 to 2.5 × 10
4
sorted TAMs were co-cultured with 2 × 10
5 naive sple-
nocytes (1:2-1:8) and 1 μg/ml anti-CD3. To neutralize
IL-10 and TGF-b, 500 ng/ml IL-10 and/or TGF-b mAb
were added to the wells containing MHC class II
low
TAMs, followed by BrdU staining 24 h later. T cell pro-
liferation was assessed using a commercial ELISA kit
(Roche Diagnostics, GmbH, Mannheim, Germany),
according to the manufacturer’s instructions.
ELISA
The co-culture supernatants were collected and stored
at -80°C until used. IL-10 and TGF-b levels were mea-
sured using commercially available ELISA kits (Bender
Medsystems) according to the manufacturer’s
instructions.
Adoptive transfer of distinct TAM subsets
For the adoptive transfer assays, 2 × 10
6 sorted F4/80
+MHC II
hi and F4/80
+MHC II
low cells were injected,
into the tumors of mice 2 days after inoculation of
Hepa1-6 cells. PBS was used as the control. Tumor size
was measured every 4 days. The mice were sacrificed 10
days after adoptive transfer and the tumors dissected
out for further analysis.
Statistical analysis
Statistical significance was determined using the Stu-
dent’s t test and GraphPad Prism software. Data were
expressed as the mean ± SD. A p value < 0.05 was con-
sidered significant.
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